Pablo Corral on Why Early LDL-C Reduction Saves Lives
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Statins:
- The Power of Early Intervention and the Reality of the Legacy Effect
- The long arc of cardiovascular prevention continues to point in one direction: earlier LDL-C reduction delivers deeper, long-lasting protection. Two landmark analyses reinforce this principle with remarkable clarity.
The Scandinavian Simvastatin Survival Study (4S)—now revisited three decades after its publication—established that intensive LDL-C lowering not only reduces cardiovascular events but fundamentally alters long-term disease trajectories.
Its impact initiated a paradigm shift in dyslipidaemia management that persists today. (10.1016/S0140-6736(24)02089-0)
The ASCOT-Legacy 20-year follow-up extends this insight even further.
Despite convergence of lipid levels after trial completion, participants originally randomised to atorvastatin maintained significant long-term reductions in non-fatal myocardial infarction, fatal coronary heart disease, total coronary events, and cardiovascular mortality—demonstrating a true “legacy effect.”
Each 1 mmol/L lower in-trial LDL-C was associated with substantial long-term reductions in cardiovascular and all-cause mortality. (10.1136/heartjnl-2024-325104)
Key message:
- Statins do more than lower LDL-C today—they reduce the cumulative cholesterol burden that determines tomorrow’s risk.
- Starting earlier, treating consistently, and achieving lower LDL-C levels is not aggressive medicine—it is simply good medicine.
As the evidence mounts, the clinical imperative becomes harder to ignore:
Delay is costly.
Early, sustained lipid-lowering therapy saves lives.”
Stay updated with Hemostasis Today.
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC
-
Jan 25, 2026, 12:17Natalie Arnold on 11 Clinical Trials That Will Shape Medicine in 2026
-
Jan 25, 2026, 12:05Wolfgang Miesbach on GTH Certification Program for Haemophilia Centres in German-Speaking Countries
-
Jan 25, 2026, 11:46Luma Mahairi on What High-Functioning Teams Can Learn From The Blood System
-
Jan 24, 2026, 15:54Nicolas Nesseler on How Common and Serious is Post-Op Bleeding After Heart Transplantation
-
Jan 24, 2026, 15:43Roey Tagansky on Tu Youyou and the Rediscovery That Defeated Malaria
-
Jan 24, 2026, 15:27Mavis Agnes Kisakye on Community Impact at HFU
-
Jan 24, 2026, 15:15Jo Jewell Announces Novartis Foundation and Novo Nordisk Collaboration